ABBV

ABBVIE
D

ABBV

Arincen73/100B
294.86
USD
9.02
(3.16%)
Post Trading·295.20USD+0.34(+0.12%)
Last updated: · Delayed 15 min
Fair value398.80Plus-26%299Price 294.86499
Q4 FY2026 · Earnings report
EPS estimate 3.89Revenue estimate 18.33B
OverviewFinancialsSignalsNewsForecastEarningsDividendsCompany

ABBVIE revenue 2009–2026

ABBVIE's revenue in Q3 FY2026, the three months to 30 September 2026, was 17.40B USD, up 10.3% on the same quarter a year before. ABBVIE's revenue over the last twelve months was 66.01B USD, up 10.7% on the twelve months before. In fiscal year 2025 it was 61.16B USD, up 8.6% on the year before.

Last updated 4 Nov 2026 · Next report 3 Feb 2027

Revenue

Growth

Fiscal yearPeriod endingRevenueGrowthGross profitNet income
TTM30 Sept 202666.01B+10.68%50.34B10.35B
FY202531 Dec 202561.16B+8.57%42.96B4.23B
FY202431 Dec 202456.33B+3.71%39.43B4.28B
FY202331 Dec 202354.32B-6.44%33.90B4.86B
FY202231 Dec 202258.05B+3.30%40.64B11.84B
FY202131 Dec 202156.20B+22.69%38.75B11.54B
FY202031 Dec 202045.80B+37.69%30.42B4.62B
FY201931 Dec 201933.27B+1.57%25.83B7.88B
FY201831 Dec 201832.75B+16.08%25.04B5.69B
FY201731 Dec 201728.22B+10.06%21.18B5.31B
FY201631 Dec 201625.64B+12.16%19.81B5.95B
FY201531 Dec 201522.86B+14.52%18.36B5.14B
FY201431 Dec 201419.96B+6.23%15.53B1.77B
FY201331 Dec 201318.79B+2.23%14.21B4.13B
FY201231 Dec 201218.38B+5.37%13.87B5.28B
FY201131 Dec 201117.44B+11.55%12.81B3.43B
FY201031 Dec 201015.64B+10.02%11.35B4.18B
FY200931 Dec 200914.21B—10.16B4.64B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

ABBVIE revenue growth by segment

Q3 FY2026 against Q3 FY2025

SKYRIZI5.78B
+22.7%
RINVOQ2.71B
+23.9%
Botox Therapeutic1.08B
+9.6%
Vraylar1.07B
+14.3%
Other Products1.01B
+53.5%
VENCLEXTA803.00M
+10.6%
H U M I R A683.00M
-31.2%
Botox Cosmetic669.00M
+5.0%
Imbruvica522.00M
-26.1%
Ubrelvy449.00M
+26.8%
Qulipta398.00M
+38.2%
Linzess/Constella339.00M
+4.0%
Other Aesthetics285.00M
-5.9%
MAVYRET265.00M
-15.1%
Juvederm Collection222.00M
-12.3%
Other Neuroscience108.00M
+134.8%

ABBVIE revenue by segment over time

SKYRIZI RINVOQ H U M I R A Botox Therapeutic Vraylar Imbruvica VENCLEXTA Other Products Botox Cosmetic MAVYRET Ubrelvy Other Aesthetics Qulipta Other Eye Care Juvederm Collection Linzess/Constella Ozurdex Lumigan/Ganfort Duodopa Other Neuroscience Alphagan/Combigan Creon Restasis
Fiscal yearSKYRIZIRINVOQH U M I R ABotox TherapeuticVraylarImbruvicaVENCLEXTAOther ProductsBotox CosmeticMAVYRETUbrelvyOther AestheticsQuliptaOther Eye CareJuvederm CollectionLinzess/ConstellaOzurdexLumigan/GanfortDuodopaOther NeuroscienceAlphagan/CombiganCreonRestasis
FY202517.56B +49.9%8.30B +39.1%4.54B -49.5%3.77B +14.8%3.62B +10.8%2.87B -14.3%2.79B +8.1%2.63B -13.4%2.60B -4.3%1.32B +0.5%1.27B +26.3%1.27B -1.1%1.04B +57.4%1.01B +19.1%993.00M -15.6%907.00M -4.9%493.00M -0.2%410.00M -4.4%381.00M -14.8%207.00M -38.8%197.00M -20.6%— —
FY202411.72B +50.9%5.97B +50.4%8.99B -37.6%3.28B +9.8%3.27B +18.4%3.35B -6.9%2.58B +12.9%3.03B -0.1%2.72B +1.4%1.31B -8.3%1.01B +23.4%1.28B +3.6%658.00M +61.3%847.00M +5.5%1.18B -14.6%954.00M -13.9%494.00M +4.7%429.00M -0.7%447.00M -4.5%338.00M +22.5%248.00M -8.8%— 224.00M -48.6%
FY20237.76B +50.3%3.97B +57.4%14.40B -32.2%2.99B +10.0%2.76B +35.4%3.60B -21.3%2.29B +13.9%3.04B -26.6%2.68B +2.6%1.43B -7.2%815.00M 1.23B -4.3%408.00M 803.00M -31.7%1.38B -3.5%1.11B +7.1%472.00M 432.00M -16.0%468.00M +2.2%276.00M -41.9%272.00M -21.4%— 436.00M -34.5%
FY20225.17B +75.7%2.52B +52.8%21.24B +2.6%2.72B +10.9%2.04B 4.57B -15.5%2.01B +10.4%4.14B +54.8%2.62B +17.2%1.54B -9.9%— 1.29B -12.0%— 1.18B +0.5%1.43B -7.0%1.04B -0.3%— 514.00M -11.2%458.00M -10.4%475.00M -30.7%346.00M -34.6%— 666.00M -48.4%
FY20212.94B +84.8%1.65B +125.9%20.69B +4.3%2.45B +76.7%— 5.41B +1.8%1.82B +36.1%2.67B -8.6%2.23B +100.7%1.71B -6.6%— 1.47B +92.9%— 1.17B +68.7%1.54B +113.8%1.04B +55.6%— 579.00M +53.2%511.00M +3.4%685.00M +27.1%529.00M +62.3%— 1.29B +63.9%
FY20201.59B +347.9%731.00M +1,455.3%19.83B +3.5%1.39B — 5.31B +13.7%1.34B +68.8%2.92B +472.0%1.11B 1.83B -36.7%— 760.00M — 693.00M 718.00M 667.00M — 378.00M 494.00M +7.2%539.00M 326.00M — 787.00M
FY2019355.00M 47.00M 19.17B -3.8%— — 4.67B +30.2%792.00M +130.2%511.00M +60.2%— 2.89B -15.9%— — — — — — — — 461.00M +7.2%— — — —
FY2018— — 19.94B +8.2%— — 3.59B +39.5%344.00M 319.00M -68.0%— 3.44B — — — — — — — — 430.00M +21.1%— — — —
FY2017— — 18.43B +14.6%— — 2.57B +40.4%— 998.00M -18.0%— — — — — — — — — — 355.00M +21.2%— — 831.00M +13.8%—
FY2016— — 16.08B +14.7%— — 1.83B +143.0%— 1.22B -0.5%— — — — — — — — — — 293.00M +26.8%— — 730.00M +15.5%—

See also:Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about ABBVIE's revenue

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.